Medicare Advantage plans may see higher healthcare spending on end-stage renal disease (ESRD) populations when the new Medicare Advantage and Part D rule goes into effect, an Avalere study found. Earlier in 2020, CMS finalized a rule that allowed patients with ESRD to enroll in a Medicare Advantage plan. The rule was controversial for its reimbursement policy, which many plans and organizations found to be too low to cover the costs of ESRD treatment.
|